Clinical Trial

Phase 3 Clinical Study of AK112 for NSCLC Patients

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2022-01-07; most recent amendment 2026-03-02.
Status change: Recruiting → Active, Not Recruiting 2024-06-24
Status change: Not Yet Recruiting → Recruiting 2022-05-23
Trial Details
NCT Number NCT05184712
Lead Sponsor Akeso
Conditions Non-Squamous Non-small Cell Lung Cancer
Enrollment 322 participants
Start Date 2022-01-25
Primary Completion 2023-03-10 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-04